17 results match your criteria: "New York University School of Medicine (S.B.[Affiliation]"
Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus.
Circ Cardiovasc Qual Outcomes
November 2018
Department of Cardiology, Zuckerberg San Francisco General Hospital, CA (D.D.W.).
Background: Some studies have shown that body weight variability is a risk factor for cardiovascular events, but this has not been studied in subjects with diabetes mellitus.
Methods And Results: We measured intraindividual variations in body weight from baseline and follow-up visits in 6408 subjects with type 2 diabetes mellitus from 3 clinical trials. The primary end point, any coronary event, was a composite of coronary heart disease death, myocardial infarction, resuscitated cardiac arrest, coronary revascularization, and unstable or new-onset angina.
Age, Blood Pressure Targets, and Guidelines: Rift Between Those Who Preach, Those Who Teach, and Those Who Treat?
Circulation
July 2018
Gill Heart & Vascular Institute, University of Kentucky, Lexington (A.W.M.).
Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease.
Circulation
November 2018
New York Presbyterian Hospital, Columbia University Medical Center and the Cardiovascular Research Foundation (G.W.S.).
Background: Contemporary second-generation drug-eluting stents (DES) have superior efficacy and safety in comparison with early-generation stents in patients undergoing percutaneous coronary intervention, in part, related to their thinner struts. Whether newer-generation ultrathin DES further improve clinical outcomes in comparison with older second-generation thicker strut DES is unknown.
Methods: We searched PubMed, Embase, and Cochrane Central Register of Controlled Trials for randomized clinical trials that compared newer-generation ultrathin strut DES (defined as strut thickness <70 µm) versus thicker strut second-generation DES and reported clinical outcomes.
When Guideline Authors Ignore Their Own Guidelines.
Hypertension
July 2018
From the Department of Cardiology, University of Bern, Switzerland (F.H.M., S.F.R., E.R.).
ISCHEMIA: Establishing the Primary End Point.
Circ Cardiovasc Qual Outcomes
May 2018
New York University School of Medicine (S.B., H.R.R., J.S.H.).
Device Thrombosis After Percutaneous Left Atrial Appendage Occlusion Is Related to Patient and Procedural Characteristics but Not to Duration of Postimplantation Dual Antiplatelet Therapy.
Circ Cardiovasc Interv
March 2018
From the Coronary and Structural Heart Diseases Department (R.P., Z.D., C.K., M.K., E.K.-D., J.P.-M., S.B., M.S., A.P., A.D., B.S., A.P., M.D.), Congenital Heart Diseases Department (M.K.), and Interventional Cardiology and Angiology Department (A.W.), Institute of Cardiology, Warsaw, Poland; Department of Medicine, New York University School of Medicine (S.B.); and Coronary and Structural Heart Diseases Department, Institute of Cardiology, Warsaw, Poland (W.R.).
Background: Device-related thrombus (DRT) after left atrial appendage occlusion is a worrisome finding with little knowledge about when to expect it and how to prevent it. This study sought to investigate correlates of DRT after left atrial appendage occlusion, its time of diagnosis, and particularly, association with postimplantation dual antiplatelet therapy duration.
Methods And Results: Consecutive patients (n=102) after left atrial appendage occlusion with AMPLATZER Cardiac Plug/Amulet (n=59) or WATCHMAN (n=43) were included in a prospective registry (October 2011-May 2016).
Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Non-ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States.
Circ Cardiovasc Qual Outcomes
September 2017
From the Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Boston (E.A.S.); Harvard Medical School, Boston, MA (E.A.S., E.G.F., L.M., R.W.Y.); Smith Center for Outcomes Research in Cardiology; Beth Israel Deaconess Medical Center, Boston, MA (E.A.S., R.W.Y.); Division of Cardiology, Department of Medicine, Center for Interventional Vascular Therapy, New York, NY (A.K.); Columbia University, New York, NY (A.K.); Division of Cardiology, Department of Medicine, New York University School of Medicine (S.B.); Division of Cardiology, Department of Medicine, Virginia Commonwealth University, Richmond, VA (I.S.J., D.P.); Division of Cardiology, Department of Medicine; Christiana Care Health System, Newark, DE (N.J.W.); Duke Clinical Research Institute, Duke University, Durham, NC (M.R., D.D.); and Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA (L.M.).
Background: Practice patterns in anticoagulant strategies used during percutaneous coronary intervention (PCI) in the United States for patients with non-ST-segment-elevation myocardial infarction and the comparative outcomes between bivalirudin and unfractionated heparin (UFH) have not been well described.
Methods And Results: Trends in anticoagulant use were examined among 553 562 PCIs performed by 9254 operators at 1538 hospitals for non-ST-segment-elevation myocardial infarction from 2009 to 2014 within the CathPCI Registry. To compare bivalirudin with UFH, propensity score matching and instrumental variable (IV) methods with operator preference for bivalirudin as the instrument were used.
Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction.
Circulation
May 2017
From Department of Cardiology and Clinical Research, University Hospital, Bern, Switzerland (F.H.M.); Jagiellonian University, Krakow, Poland (F.H.M.); Division of Cardiology, Mount Sinai Health Medical Center, Icahn School of Medicine, New York, NY (F.H.M.); and Leon H. Charney Division of Cardiology, New York University School of Medicine (S.B.).
Preventive Strategies for Contrast-Induced Acute Kidney Injury: And the Winner Is….
Circ Cardiovasc Interv
May 2017
From the Department of Medicine, Cardiovascular Clinical Research Center, New York University School of Medicine (S.B.); and Clinica Mediterranea, Naples, Italy (C.B.).
Body-Weight Fluctuations and Outcomes in Coronary Disease.
N Engl J Med
April 2017
From the New York University School of Medicine (S.B.), Pfizer (R.F., R.L., D.A.D.), and the Mount Sinai Icahn School of Medicine (F.H.M.) - all in New York; University Hospital, Bern, Switzerland (F.H.M.); Jagiellonian University, Krakow, Poland (F.H.M.); and San Francisco General Hospital, San Francisco (D.D.W.).
Background: Body-weight fluctuation is a risk factor for death and coronary events in patients without cardiovascular disease. It is not known whether variability in body weight affects outcomes in patients with coronary artery disease.
Methods: We determined intraindividual fluctuations in body weight from baseline weight and follow-up visits and performed a post hoc analysis of the Treating to New Targets trial, which involved assessment of the efficacy and safety of lowering low-density lipoprotein cholesterol levels with atorvastatin.
β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial.
Circ Cardiovasc Qual Outcomes
November 2014
From the New York University School of Medicine (S.B.); Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.); AP-HP, Hôpital Bichat, Paris, France (P.G.S.); State University of New York, Downstate College of Medicine, Brooklyn (M.A.W.); Samuel Stratton VA Medical Center, Albany Medical College, NY (W.E.B.); Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.); Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France (G.M.); Cleveland Clinic, OH (A.H., A.M.L.); and Centre for Cardiovascular Science, University of Edinburgh Duke of Edinburgh, Edinburgh, United Kingdom (K.A.A.F.).
Background: The long-term efficacy of β-blockers in patients with and without myocardial infarction (MI) is controversial.
Methods And Results: This is post hoc analysis from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial of 4772 patients with prior MI, 7804 patients with known atherothrombosis, and 2101 patients with risk factors alone but without heart failure. Primary outcome was a composite of nonfatal MI, stroke, or cardiovascular mortality.
Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Hypertension
November 2014
From the Department of Epidemiology (P.M.) and Cardiovascular Disease (D.A.C.), University of Alabama at Birmingham; Coordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston (B.R.D., S.L.P.); Preventive Medicine Section, Memphis Veterans Affairs Medical Center, TN (W.C.C.); Cardiovascular Outcomes Group, New York University School of Medicine (S.B.); New York University Langone Medical Center (H.R.B.); Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ (J.B.K.); Clinical Trials Services Unit, University of Washington School of Medicine, Seattle (J.L.P.); Global Public Health, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA (P.K.W.); Division of Nephrology and Hypertension, Case Western Reserve University, University Hospitals Case Medical Center, Cleveland, OH (M.R.); and Louis Stokes Cleveland Veterans Administration Medical Center, Cleveland, OH (M.R.).
Apparent treatment-resistant hypertension (aTRH) is defined as uncontrolled hypertension despite the use of ≥3 antihypertensive medication classes or controlled hypertension while treated with ≥4 antihypertensive medication classes. Although a high prevalence of aTRH has been reported, few data are available on its association with cardiovascular and renal outcomes. We analyzed data on 14 684 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants to determine the association between aTRH (n=1870) with coronary heart disease, stroke, all-cause mortality, heart failure, peripheral artery disease, and end-stage renal disease.
View Article and Find Full Text PDFOutcomes with coronary artery bypass graft surgery versus percutaneous coronary intervention for patients with diabetes mellitus: can newer generation drug-eluting stents bridge the gap?
Circ Cardiovasc Interv
August 2014
From the Division of Cardiology, New York University School of Medicine (S.B., F.F.); and Division of Cardiology, Virginia Commonwealth University, Richmond (B.T.).
Background: Coronary artery bypass graft surgery (CABG) compared with percutaneous coronary intervention (PCI) reduces mortality in patients with diabetes mellitus. However, prior trials compared CABG with balloon angioplasty or older generation stents, and it is not known if the gap between CABG and PCI can be reduced by newer generation drug-eluting stents.
Methods And Results: PUBMED/EMBASE/CENTRAL search for randomized trials comparing mode of revascularization in patients with diabetes mellitus.
Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry.
Circ Cardiovasc Interv
June 2014
From the Department of Medicine, Division of Cardiology, New York University School of Medicine (S.B.); Department of Biostatistics and Bioinformatics, Duke Clinical Research Institute, Durham, NC (M.J.P.); Department of Cardiology, The Methodist DeBakey Heart and Vascular Center, Houston, TX (N.S.K.); and Department of Cardiology, Saint-Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine (D.J.C.).
Background: The use of bivalirudin versus unfractionated heparin monotherapy in patients without ST-segment-elevation myocardial infarction is not well defined.
Methods And Results: The study population consisted of patients enrolled in the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry with either non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease, who underwent percutaneous coronary intervention with either unfractionated heparin or bivalirudin monotherapy. Propensity score matching was used to adjust for baseline characteristics.
Renal denervation for resistant hypertension?
N Engl J Med
April 2014
From the Division of Cardiology, Mount Sinai Roosevelt Hospital, Icahn School of Medicine (F.H.M.), and the Leon H. Charney Division of Cardiology, New York University School of Medicine (S.B.) - both in New York.